Gyre Therapeutics appoints three new directors to its board, effective August 1, 2026

GYRE THERAPEUTICS, INC.

Yue Xiong (CSO) appointed as Class I director; no additional compensation for board service.
Maxwell Kirkby appointed as Class II director and to Compensation Committee; receives 40k stock options vesting over 3 years.
Claire Weston appointed as Class III director and to Audit Committee; receives same option grant.
Appointments expand board expertise in scientific, clinical development, and cross-border operations.
Effective date August 1, 2026; terms expire at 2027, 2028, and 2029 annual meetings respectively.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.